General Biologicals Past Earnings Performance
Past criteria checks 0/6
General Biologicals has been growing earnings at an average annual rate of 8.1%, while the Biotechs industry saw earnings growing at 17.8% annually. Revenues have been growing at an average rate of 13% per year.
Key information
8.1%
Earnings growth rate
19.2%
EPS growth rate
Biotechs Industry Growth | 12.2% |
Revenue growth rate | 13.0% |
Return on equity | -27.3% |
Net Margin | -58.6% |
Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How General Biologicals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 23 | 278 | -163 | 183 | 29 |
31 Mar 23 | 324 | -108 | 180 | 33 |
31 Dec 22 | 370 | -53 | 177 | 36 |
30 Sep 22 | 415 | -24 | 187 | 36 |
30 Jun 22 | 460 | 6 | 197 | 37 |
31 Mar 22 | 506 | 25 | 200 | 35 |
31 Dec 21 | 552 | 44 | 204 | 34 |
30 Sep 21 | 590 | 81 | 199 | 40 |
30 Jun 21 | 629 | 117 | 194 | 46 |
31 Mar 21 | 553 | 90 | 180 | 44 |
31 Dec 20 | 476 | 62 | 167 | 41 |
30 Sep 20 | 377 | 21 | 143 | 39 |
30 Jun 20 | 279 | -21 | 119 | 36 |
31 Mar 20 | 259 | -30 | 122 | 36 |
31 Dec 19 | 240 | -39 | 126 | 36 |
30 Sep 19 | 243 | -54 | 140 | 33 |
30 Jun 19 | 246 | -68 | 155 | 31 |
31 Mar 19 | 245 | -69 | 153 | 30 |
31 Dec 18 | 244 | -69 | 150 | 30 |
30 Sep 18 | 235 | -67 | 150 | 30 |
30 Jun 18 | 227 | -65 | 149 | 30 |
31 Mar 18 | 207 | -73 | 143 | 33 |
31 Dec 17 | 188 | -81 | 137 | 36 |
30 Sep 17 | 185 | -80 | 120 | 41 |
30 Jun 17 | 182 | -78 | 102 | 45 |
31 Mar 17 | 183 | -82 | 99 | 48 |
31 Dec 16 | 185 | -86 | 96 | 50 |
30 Sep 16 | 183 | -85 | 99 | 55 |
30 Jun 16 | 181 | -84 | 103 | 59 |
31 Mar 16 | 175 | -83 | 97 | 62 |
31 Dec 15 | 168 | -82 | 91 | 65 |
30 Sep 15 | 167 | -76 | 85 | 65 |
30 Jun 15 | 165 | -71 | 78 | 66 |
31 Mar 15 | 182 | -51 | 75 | 57 |
31 Dec 14 | 199 | -31 | 73 | 49 |
30 Sep 14 | 205 | -19 | 70 | 40 |
30 Jun 14 | 211 | -6 | 66 | 31 |
31 Mar 14 | 203 | 0 | 68 | 29 |
31 Dec 13 | 195 | 6 | 70 | 26 |
30 Sep 13 | 190 | 16 | 75 | 25 |
30 Jun 13 | 185 | 25 | 79 | 24 |
Quality Earnings: 4117 is currently unprofitable.
Growing Profit Margin: 4117 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4117 is unprofitable, but has reduced losses over the past 5 years at a rate of 8.1% per year.
Accelerating Growth: Unable to compare 4117's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4117 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-13.8%).
Return on Equity
High ROE: 4117 has a negative Return on Equity (-27.3%), as it is currently unprofitable.